Alector, Inc. Common Stock ALEC
Analyst Ratings
- Consensus
- Moderate Buy — 3 Buy · 2 Hold · 0 Sell (5 analysts)
- Avg. Price Target
- $5.50 (+135.0% upside)
Key Stats
- Today's Range
- $2.31 – $2.44
- 50-Day Range
- $1.37 – $2.52
- 52-Week Range
- $1.09 – $3.40
- Volume
- 542K shs
- Average Volume
- 1.19 million shs
- Market Cap
- $261.28 million
- P/E Ratio
- —
- Dividend Yield
- —
Valuation
- P/E Ratio
- —
- Price / Book
- -26.21
- Price / Sales
- 18.85
Short Interest
- Short Interest
- 0.58%
- Days to Cover
- 1.00
Financials (TTM)
- Revenue
- $13.86 million
- Net Income
- $-117,854,000
- Net Margin
- -850.13%
- Return on Equity
- 1182.09%
- Debt-to-Equity
- —
About Alector, Inc. Common Stock
Alector Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company advances a pipeline of product candidates including Nivisnebart (AL101/GSK4527226) for Alzheimer's disease, AL137 for Alzheimer's disease, AL050 for Parkinson's disease and Lewy body dementia, and AL064, an siRNA program targeting tau for Alzheimer's disease and other tauopathies, supported by its proprietary Alector Brain Carrier (ABC) platform designed to improve delivery of therapeutics across the blood-brain barrier.
Related Stocks
Compare head-to-head: ALEC vs AMGN·ALEC vs MRNA·ALEC vs HALO·ALEC vs KRYS
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.